Abstract
Clinical use of peripheral blood progenitor cell (PBPC) transplantation following high-dose chemotherapy is increasingly used in the treatment of solid tumours and haematologic malignancies. As compared with rescue by autologous bone marrow cells, restoration with peripheral blood progenitor cells (PBPC) shortens the period of pancytopenia post transplantation and reduces the risk of infection and bleeding.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilisation of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636–40.
Rill DR, Santana VM, Roberts WM. et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380–83.
Brugger W, Henschler R, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carbo-platin and epirubicin. Blood 1994;84:1421–26.
Brugger W, Möcklin W, Heimfeld S, Berenson RH, Mertelsmann, Kanz L. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor interleukin-1β (IL-1β), 11–6, IL-3, interferon-y and erythropoietin. Blood 1993;81: 2579–84.
Henschler R, Brugger W, Luft T, Frey T, Mertelsmann R, Kanz L. Maintenance of transplantation potential ex vivo expanded CD34+ selected human peripheral blood progenitor cells. Blood 1994;84:2898–903.
Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. New Engl J Med 1995;333:283–87.
Brugger W, Frisch J, Schultz G, Pressler K, Mertelsmann R, Kanz L. Sequential administration of interleukin-3 and granulocyte-macrophage colony stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 1992;10:1452–59.
Brugger W, Birken R, Bertz H, et al. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophils and platelet recovery after high-dose VP16, ifosfamide, and cisplatin. Br J Hematol 1993;84:402–07.
Vogel W, Behringer D, Scheding S, Kanz L, Brugger W. Ex vivo expansion of CD34+ peripheral blood progenitor cells: Implications for the expansion of contaminating epithelial tumor cells. Blood 1996;88:2707–13.
Orlic D, Bodine BM. What defines a pluripotent hematopoietic stem cell (PHSC): Will the real PHSC stand Up! Blood 1994;84:3991–94.
Dick JE, Lapidot T, Pflumino F. Transplantation of normal leukemic human bone marrow into immune deficient mice: Development of animal models for human hematopoiesis. Immunol Rev 1991;124:25–43.
Bock TA, Orlic D, Dunbar CE, Broxmeyer CE, Bodine DM. Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes. J Exp Med 1995;182:2037–43.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Kluwer Academic Publishers
About this chapter
Cite this chapter
Bock, T.A., Brugger, W., Scheding, S., Ziegler, B., Kanz, L. (1997). Haematopoietic Growth Factors for the Expansion of Peripheral Blood Progenitor Cells. In: Sibinga, C.T.S., Das, P.C., Löwenberg, B. (eds) Cytokines and Growth Factors in Blood Transfusion. Developments in Hematology and Immunology, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1137-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1137-9_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8435-2
Online ISBN: 978-1-4613-1137-9
eBook Packages: Springer Book Archive